Wegovy vs Mounjaro: Which Is Better for Weight Loss in 2026?
Wegovy and Mounjaro both work for weight loss — but one consistently outperforms the other in clinical trials. Here's what the data actually shows.
🔑 Key Takeaways
- Wegovy (semaglutide) and Mounjaro (tirzepatide) are both injectable weight loss medications — but they work differently
- Mounjaro targets two hormones (GLP-1 + GIP), Wegovy targets one (GLP-1)
- Trial data shows Mounjaro produces ~20-22% weight loss vs ~15% for Wegovy
- Both cost roughly $1,000–$1,300/month without insurance
- Researchers can access tirzepatide and semaglutide peptides for study at a fraction of the cost
Two medications. Same goal. Very different results.
If you've been trying to figure out whether Wegovy or Mounjaro is the better choice for weight loss, you're not alone — it's one of the most Googled health questions right now. Both drugs have transformed how we think about obesity treatment. But the numbers don't lie: one of them consistently produces more weight loss. Here's what you need to know.
What Is Wegovy?
Wegovy is the brand name for semaglutide 2.4mg, manufactured by Novo Nordisk. It's a once-weekly subcutaneous injection approved by the FDA specifically for chronic weight management in adults with obesity or overweight (with at least one weight-related condition).
Semaglutide was originally developed as a diabetes drug (Ozempic uses a lower 1mg dose). Wegovy uses a higher 2.4mg dose and is specifically approved for weight loss. It works by mimicking GLP-1 — a hormone released after eating that signals fullness to your brain and slows gastric emptying.
The STEP clinical trials showed Wegovy users lost an average of ~15% of body weight over 68 weeks — more than any previous weight loss drug at the time. That was a big deal. Then tirzepatide came along.
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide, made by Eli Lilly. Here's where it gets slightly complicated: Mounjaro is FDA-approved for type 2 diabetes management. Zepbound is the same molecule approved specifically for weight loss. In practice, many people use Mounjaro off-label for weight loss — especially before Zepbound became widely available.
For the purposes of this comparison, we're talking about tirzepatide in any form (Mounjaro or Zepbound) used for weight loss.
💡 Note
Mounjaro = tirzepatide for diabetes. Zepbound = tirzepatide for weight loss. Same molecule, different labeling. Both are weekly injections with identical dosing schedules.
Tirzepatide doses range from 2.5mg up to 15mg weekly, with gradual dose escalation over several months. The dosing flexibility is one reason researchers and clinicians find it interesting.
The Core Mechanism Difference
This is the key. Understanding why Mounjaro wins on weight loss requires understanding how these drugs actually work.
Wegovy (semaglutide) is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a gut hormone that:
- Slows stomach emptying
- Reduces appetite by signaling the hypothalamus
- Stimulates insulin secretion when blood sugar rises
- Suppresses glucagon (the hormone that raises blood sugar)
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist. It hits both GLP-1 (same as Wegovy) AND GIP — glucose-dependent insulinotropic polypeptide. GIP is released from the small intestine and plays a role in fat storage and energy metabolism.
Wegovy: Single Target
GLP-1 receptor only. Proven appetite suppression and gastric slowdown. Excellent results — ~15% weight loss in trials.
Mounjaro: Dual Target
GLP-1 + GIP receptors. The added GIP effect appears to enhance fat metabolism and amplify weight loss beyond what GLP-1 alone achieves.
Why Dual Agonism Matters
GIP receptors in adipose tissue may enhance the GLP-1 effect, leading to greater fat loss. The combination seems to be more than additive.
The Practical Result
Tirzepatide users in trials lost 20-22% of body weight — consistently outperforming semaglutide head-to-head in comparative analyses.
Weight Loss Results: The Trial Data
Let's look at what the actual trial data shows. No hype — just numbers.
| Drug | Trial | Duration | Mean Weight Loss | Placebo |
|---|---|---|---|---|
| Semaglutide 2.4mg (Wegovy) | STEP 1 | 68 weeks | 14.9% | 2.4% |
| Tirzepatide 15mg (Mounjaro/Zepbound) | SURMOUNT-1 | 72 weeks | 20.9% | 3.1% |
| Tirzepatide 10mg | SURMOUNT-1 | 72 weeks | 19.5% | 3.1% |
| Tirzepatide 5mg | SURMOUNT-1 | 72 weeks | 15.0% | 3.1% |
At the highest doses, tirzepatide consistently beats semaglutide. Some participants in SURMOUNT-1 lost over 22% of body weight — territory that was previously only associated with bariatric surgery.
There's no direct head-to-head RCT between the two drugs (as of 2026), so the comparison relies on cross-trial analysis. But the pattern is consistent: tirzepatide's dual mechanism translates to meaningfully greater weight loss in most patients.
Side Effects Compared
Both drugs share a similar side effect profile — which makes sense given they both activate GLP-1 receptors. The most common issues are GI-related.
| Side Effect | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Nausea | 44% | ~40% |
| Diarrhea | 30% | ~23% |
| Vomiting | 24% | ~21% |
| Constipation | 24% | ~17% |
| Injection site reactions | Yes (mild) | Yes (mild) |
| Pancreatitis risk | Rare, possible | Rare, possible |
| Thyroid C-cell tumors (animal data) | Contraindicated if personal/family MTC history | Same contraindication |
GI side effects typically peak during dose escalation and improve over time. Most people find them manageable if they eat smaller portions, avoid greasy foods, and stick to the dose schedule.
One notable concern with both drugs: muscle loss. Clinical trials show a significant portion of weight lost can come from lean mass, not just fat. Resistance training and adequate protein intake are usually recommended alongside these medications.
Cost & Insurance Coverage
Here's the painful part.
| Wegovy | Mounjaro/Zepbound | |
|---|---|---|
| List price (monthly) | ~$1,349 | ~$1,059–$1,349 |
| With insurance (varies) | $0–$200+ | $0–$200+ |
| Manufacturer savings card | Yes (income-limited) | Yes (income-limited) |
| Medicare coverage | Limited (improving) | Limited (improving) |
Insurance coverage for weight loss drugs is still inconsistent. Many plans exclude them outright. Some employers have started covering them due to long-term cost savings from reduced diabetes and cardiovascular disease — but it depends entirely on your plan.
Eli Lilly's savings card for Zepbound can bring the out-of-pocket cost down significantly for commercially insured patients. Novo Nordisk has a similar program for Wegovy. Both require you to qualify.
Which One Is Right for You?
The data leans toward tirzepatide for maximum weight loss. But "best on average" doesn't mean "best for you."
Consider Wegovy (semaglutide) if:
- Your insurance specifically covers it
- You've already started on Ozempic and want to transition to the weight loss dose
- You prefer a medication with longer real-world safety data
- You're sensitive to GI side effects and want to try the lower-risk option first
Consider Mounjaro/Zepbound (tirzepatide) if:
- Maximum weight loss is your primary goal
- You have type 2 diabetes alongside obesity
- Previous GLP-1 medications haven't given you enough results
- Your insurance covers Mounjaro or you can access the savings card
💡 Note
The "best" medication is always the one you can actually access, afford, and tolerate. An affordable drug you can stick with beats a more effective one you stop after two months.
The Research Peptide Alternative
For researchers, academics, and those studying GLP-1 and dual agonist mechanisms, pharmaceutical-grade research peptides are available at a fraction of the prescription cost.
Tirzepatide (T-10) from Ascension Peptides is a high-purity research-grade tirzepatide compound used in scientific investigation of dual GIP/GLP-1 receptor pharmacology. It's not a pharmaceutical drug and is intended for laboratory research only — but for researchers studying peptide mechanisms, it's a practical option.
View Tirzepatide (T-10) on Ascension Peptides →
Ascension also carries Semaglutide (S-5) for researchers studying GLP-1 receptor agonism specifically:
View Semaglutide (S-5) on Ascension Peptides →
